RADAR1- Trial of a New Blood Sample Method (Remote Arthritis Disease Activity MonitoR) (RADAR)
Rheumatoid Arthritis
About this trial
This is an interventional screening trial for Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria:
Rheumatoid Arthritis will be diagnosed according to the joint American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) 2010 criteria. Patients who are about to receive their first / a change in combination or dose of DMARD (prospective) or are currently being treated by DMARD therapy will be included in the study.
Exclusion Criteria:
Patients who have received or are receiving biologic therapy will be excluded from the study. Patients will be representative of the 'real life' patient population in the clinics who meet these criteria, and will not be excluded for other general health reasons.
Sites / Locations
- Northern Ireland Centre for Stratified Medicine/ Altnagelvin Hopsital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
In Clinic monitoring
At Home monitoring
70 method comparison patients who represent a C-reactive protein (CRP) reference range and have retrievable study outcome measures will have a whole blood sample and DBSS taken at recruitment and at a routine six week review.
30 Prospective patients will provide (i) one whole blood sample and one set of dried blood spot samples (DBSS) at recruitment, (ii) a set of DBSS once a week for six weeks from recruitment, with a matched whole blood sample at six week appointment, (iii) two extra sets of DBSS to be taken during a flare and 24 hours after (iv) 6 prospective patients will have daily hand movement data collected for 5 minutes on each occasion using a provided data glove.